Pluripotent human stem cells: A novel tool in drug discovery

BioDrugs

Volumn 24, Issue 2, 2010, Pages 99-108

  Phillips, Blaine W ^a   Crook, Jeremy M ^b  

^a INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^b O'Brien Institute   (Australia)

Author keywords

Research and development; Toxicology

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUOROURACIL; RETINOIC ACID; ROFECOXIB;

CARDIOTOXICITY; CELL CULTURE; CELL DIFFERENTIATION; COST EFFECTIVENESS ANALYSIS; CULTURE TECHNIQUE; DISEASE MODEL; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG METABOLISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; EMBRYONIC STEM CELL; EMBRYOTOXICITY; HEART MUSCLE CELL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL; LIVER METABOLISM; MOLECULAR MODEL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SCALE UP; TORSADE DES POINTES; TOXICITY TESTING;

CELL CULTURE TECHNIQUES; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, GENETIC; PHARMACOKINETICS; PLURIPOTENT STEM CELLS; TOXICITY TESTS;

EID: 77949328902     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11532270-000000000-00000     Document Type: Review

References (103)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003 Mar; 22 (2): 151-85
2. Collier R. Drug development cost estimates hardto swallow. CMAJ 2009 Feb 3; 180 (3): 279-80
3. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004 May; 3 (5): 451-6
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004 Aug; 3 (8): 711-5
5. Schafer S, Kolkhof P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today 2008 Nov; 13 (21-22): 913-6
6. Gomez-Lechon MJ, Castell JV, Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 2008 Jul; 4 (7): 837-54
7. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000 Dec 19; 97 (26): 14720-5
8. Kelly HT, Hill E, Reid F, et al. Comparison of RAP-PCR analysis of gene expression in fresh and immortalised rat hepatocyte cell lines. Cyto-technology 2000 Oct; 34 (1-2): 159-63
9. Nirmalanandhan VS, Sittampalam GS. Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges. J Biomol Screen 2009 Aug 12; 14(7): 755-68
10. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev 2005 May 15; 19 (10): 1129-55
11. Nishikawa SI, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 2008 Sept; 9 (9): 725-9
12. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007 Nov 30; 131 (5): 861-72
13. Maherali N, Sridharan R, Xie W, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 2007 Jun 7; 1 (1): 55-70
14. Zhao XY, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation. Nature 2009 Sep 3; 461 (7260): 86-90
15. Boland MJ, Hazen JL, Nazor KL, et al. Adult mice generated from induced pluripotent stem cells. Nature 2009 Sep 3; 61(7260): 91-4
16. Bongso A, Fong CY, Ng SC, et al. Human embryonic behavior in a sequential human oviduct-endometrial coculture system. Fertil Steril 1994 May; 61 (5): 976-8
17. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998 Nov 6; 282 (5391): 1145-7
18. Phillips BW, Hentze H, Rust WL, et al. Directed differentiation of human embryonic stem cells into the pancreatic endocrine lineage. Stem Cells Dev 2007; 16: 561-78
19. Xu XQ, Zweigerdt R, Soo SY, et al. Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy 2008; 10 (4): 376-89
20. Cho MS, Lee YE, Kim JY, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A 2008 Mar 4; 105 (9): 3392-7
21. Zou J, Maeder ML, Mali P, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009 Jul 2; 5 (1): 97-110
22. Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluri-potent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008 Jan; 26 (1): 101-6
23. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006 Aug; 8 (126): 1-4
24. Kim JB, Zaehres H, Wu G, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008 Jul 31; 454 (7204): 646-50
25. Miura K, Okada Y, Aoi T, et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009 Aug; 27(8): 743-5
26. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008 Jul; 26(7): 795-7
27. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009 May 8; 324 (5928): 797-801
28. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009 Apr 9; 458 (7239): 766-70
29. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009 Apr 9; 458 (7239): 771-5
30. Pal R, Totey SS, Mamidi MK, et al. Propensity of human embryonic stem cell lines during early stage of lineage specification control their terminal differentiation into mature cell types. Exp Biol Med (Maywood) 2009 Oct; 234 (10): 1230-43
31. Osafune K, Caron L, Borowiak M, et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 2008 Mar; 26(3): 313-5
32. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009 Jul 2; 5 (1): 111-23
33. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008 Sep 5; 134 (5): 877-86
34. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008 Aug 29; 321 (5893): 1218-21
35. Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009 Mar; 8 (3): 203-12
36. Guguen-Guillouzo C, Corlu A, Guillouzo A. Stem cell-derived hepatocytes and their use in toxicology. Toxicology. Epub 2009 Oct 6
37. Gomez-Lechon MJ, Castell JV, Donato MT. Hepatocytes: the choice to in-vestigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem Biol Interact 2007 May 20; 168 (1): 30-50
38. Soars MG, McGinnity DF, Grime K, et al. The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 2007 May 20; 168 (1): 2-15
39. O'Brien PJ, Chan K, Silber PM. Human and animal hepatocytes in vitro with extrapolation in vivo. Chem Biol Interact 2004 Nov 1; 150 (1): 97-114
40. Borowiak M, Maehr R, Chen S, et al. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 2009 Apr 3; 4 (4): 348-58
41. Suter DM, Preynat-Seauve O, Tirefort D, et al. Phenazopyridine induces and synchronizes neuronal differentiation of embryonic stem cells. J Cell Mol Med. Epub 2009 Jan 16
42. Desbordes SC, Placantonakis DG, Ciro A, et al. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2008 Jun 5; 2 (6): 602-12
43. Frantz S. How to avoid another 'Vioxx'. Nat Rev Drug Discov 2005 Jan; 4 (1): 5-7
44. Greener M. Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval. EMBO Rep 2005 Mar; 6 (3): 202-4
45. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci. Arch Mal Coeur Vaiss 1966 Feb; 59 (2): 263-72
46. Soubret A, Helmlinger G, Dumotier B, et al. Modeling and simulation of preclinical cardiac safety: towards an integrative framework. Drug Metab Pharmacokinet 2009; 24 (1): 76-90
47. Thomsen MB, Matz J, Volders PG, et al. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 2006 Oct; 112 (1): 150-70
48. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995 Apr 21; 81 (2): 299-307
49. Hanton G, Tilbury L. Cardiac safety strategies: 25-26 October 2005, the Radisson SAS Hotel, Nice, France. Expert Opin Drug Saf 2006 Mar; 5 (2): 329-33
50. Mummery C, Ward-van Oostwaard D, Doevendans P, et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003 Jun 3; 107 (21): 2733-40
51. Xu XQ, Graichen R, Soo SY, et al. Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation 2008 Nov; 76 (9): 958-70
52. Passier R, Oostwaard DW, Snapper J, et al. Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells 2005 Jun-Jul; 23 (6): 772-80
53. Graichen R, Xu X, Braam SR, et al. Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation 2007 Nov 15; 76 (4): 357-70
54. He JQ, January CT, Thomson JA, Kamp TJ. Human embryonic stem cell-derived cardiomyocytes: drug discovery and safety pharmacology. Exp Opin Drug Discov 2007; 2 (5): 739-53
55. He JQ, Ma Y, Lee Y, et al. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 2003 Jul 11; 93 (1): 32-9
56. Zhang J, Wilson GF, Soerens AG, etal. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009 Feb 27; 104 (4): e30-41
57. Yokoo N, Baba S, Kaichi S, et al. The effects of cardioactive drugs on car-diomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun 2009 Sep 25; 387 (3): 482-8
58. Park MV, Annema W, Salvati A, et al. In vitro developmental toxicity test detects inhibition of stem cell differentiation by silica nanoparticles. Toxicol Appl Pharmacol 2009 Oct 1; 240 (1): 108-16
59. Adler S, Pellizzer C, Hareng L, et al. First steps in establishing a developmental toxicity test method based on human embryonic stem cells. Toxicol In Vitro 2008 Feb; 22 (1): 200-11
60. Abdul Kadir SH, Ali NN, Mioulane M, et al. Embryonic stem cell-derived cardiomyocytes as a model to study fetal arrhythmia related to maternal disease. J Cell Mol Med. Epub 2009 Mar 6
61. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41 (2): 89-295
62. Itskovitz-Eldor J, Schuldiner M, Karsenti D, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med 2000 Feb; 6 (2): 88-95
63. Schuldiner M, Yanuka O, Itskovitz-Eldor J, et al. Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2000 Oct 10; 97 (21): 11307-12
64. Rambhatla L, Chiu CP, Kundu P, et al. Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant 2003; 12 (1): 1-11
65. Lavon N, Yanuka O, Benvenisty N. Differentiation and isolation of hepatic-like cells from human embryonic stem cells. Differentiation 2004 Jun; 72 (5): 230-8
66. Hay DC, Fletcher J, Payne C, et al. Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci U S A 2008 Aug 26; 105 (34): 12301-6
67. Basma H, Soto-Gutierrez A, Yannam GR, et al. Differentiation and trans-plantation of human embryonic stem cell-derived hepatocytes. Gastro-enterology 2009 Mar; 136 (3): 990-9
68. Zwaka TP, Thomson JA. Homologous recombination in human embryonic stem cells. Nat Biotechnol 2003 Mar; 21 (3): 319-21
69. Xia X, Zhang SC. Genetic modification of human embryonic stem cells. Biotechnol Genet Eng Rev 2007; 24: 297-309
70. Braam SR, Denning C, van den Brink S, et al. Improved genetic manipulation of human embryonic stem cells. Nat Methods 2008 May; 5 (5): 389-92
71. Costa M, Dottori M, Ng E, et al. The hESC line Envy expresses high levels of GFP in all differentiated progeny. Nat Methods 2005 Mar 23; 2 (4): 259-60
72. Costa M, Dottori M, Sourris K, et al. A method for genetic modification of human embryonic stem cells using electroporation. Nat Protoc 2007; 2 (4): 792-6
73. Cabaniols JP, Mathis L, Delenda C. Targeted gene modifications in drug discovery and development. Curr Opin Pharmacol 2009 Oct; 9 (5): 657-63
74. Andrews PW. Response: karyotype of human EScells during extended culture [letter]. Nat Biotechnol 2004 Apr; 22 (4): 382
75. Dhara SK, Gerwe BA, Majumder A, et al. Genetic manipulation of neural progenitors derived from human embryonic stem cells. Tissue Eng Part A 2009 Nov; 15 (11): 3621-34
76. Kobayashi NR, Sui L, Tan SL, et al. Modelling disrupted-in-schizophremia 1 loss of function in human neural progenitor cells: tools for molecular studies of human neurodevelopment and neuropsychiatric disorders. Mol Psyc. Epub 2009 Dec 15
77. Verlinsky Y, Strelchenko N, Kukharenko V, et al. Human embryonic stem cell lines with genetic disorders. Reprod Biomed Online 2005 Jan; 10 (1): 105-10
78. Niclis JC, Trounson AO, Dottori M, et al. Human embryonic stem cell models of Huntington disease. Reprod Biomed Online 2009 Jul; 19 (1): 106-13
79. Eiges R, Urbach A, Malcov M, et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 2007 Nov; 1 (5): 568-77
80. Belmonte JC, Ellis J, Hochedlinger K, et al. Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat Rev Genet 2009 Dec; 10(12): 878-83
81. Abeliovich A, Doege CA. Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease. Neuron 2009 Feb 12; 61 (3): 337-9
82. Maehr R, Chen S, Snitow M, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A 2009 Sep 15; 106 (37): 15768-73
83. Ebert AD, Yu J, Rose Jr FF, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009 Jan 15; 457 (7227): 277-80
84. Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009 Sep 17; 461 (7262): 402-6
85. Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003 Oct 1; 12 (19): 2481-9
86. Cuajungco MP, Leyne M, Mull J, et al. Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. Am J Hum Genet 2003 Mar; 72 (3): 749-58
87. Mollamohammadi S, Taei A, Pakzad M, et al. A simple and efficient cryopreservation method for feeder-free dissociated human induced pluripotent stem cells and human embryonic stem cells. Hum Reprod 2009 Oct; 24(10): 2468-76
88. Phillips BW, Horne R, Lay TS, et al. Attachment and growth of human embryonic stem cells on microcarriers. J Biotechnol 2008 Nov 6; 138 (1-2): 24-32
89. Lock LT, Tzanakakis ES. Expansion and differentiation ofhuman embryonic stem cells to endoderm progeny in a microcarrier stirred-suspension culture. Tissue Eng Part A 2009 Aug; 15 (8): 2051-63
90. Nie Y, Bergendahl V, Hei DJ, et al. Scalable culture and cryopreservation of human embryonic stem cells on microcarriers. Biotechnol Prog 2009 Jan-Feb; 25 (1): 20-31
91. Oh SK, Chen AK, Mok Y, et al. Long-term microcarrier suspension cultures of human embryonic stem cells. Stem Cell Res. Epub 2009 Mar 4
92. Fernandes AM, Marinho PA, Sartore RC, et al. Successful scale-up of human embryonic stem cell production ina stirred microcarrier culture system. Braz J Med Biol Res 2009 Jun; 42 (6): 515-22
93. Levenstein ME, Ludwig TE, Xu RH, et al. Basic FGF support of human embryonic stem cell self-renewal. Stem Cells 2006 Nov 10; 24 (3): 568-74
94. Amit M, Shariki C, Margulets V, et al. Feeder layer-and serum-free culture of human embryonic stem cells. Biol Reprod 2004; 70 (3): 837-45
95. Ding V, Choo AB, Oh SK. Deciphering the importance of three key media components in human embryonic stem cell cultures. Biotechnol Lett 2006 Apr; 28 (7): 491-5
96. Phillips BW, Lim RY, Tan TT, et al. Efficient expansion of clinical-grade human fibroblasts on microcarriers: cells suitable for ex vivo expansion of clinical-grade hESCs. J Biotechnol 2008 Mar 20; 134 (1-2): 79-87
97. Bajpai R, Lesperance J, Kim M, et al. Efficient propagation of single cells accutase-dissociated human embryonic stem cells. Mol Reprod Dev 2007 Dec 21; 75 (5): 818-27
98. Hasegawa K, Fujioka T, Nakamura Y, et al. A method for the selection of human embryonic stem cell sublines with high replating efficiency after single-cell dissociation. Stem Cells 2006 Dec; 24 (12): 2649-60
99. Ellerstrom C, Strehl R, Noaksson K, et al. Facilitated expansion of human embryonic stem cells by single cell enzymatic dissociation. Stem Cells 2007 Mar 22; 25 (7): 1690-6
100. Baker DE, Harrison NJ, Maltby E, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 2007 Feb; 25 (2): 207-15
101. Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 2007 Jun; 25 (6): 681-6
102. Crook JM, Peura TT, Kravets L, et al. The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell 2007; 1 (5): 490-4
103. Maddox CB, Rasmussen L, White EL. Adapting cell-based assays to the high throughput screening platform: problems encountered and lessons learned. JALA Charlottesv Va 2008 Jun; 13 (3): 168-73